Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Conditions: Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts

Interventions: Combination Product: VP-102; Combination Product: Vehicle

Sponsors: Verrica Pharmaceuticals Inc.; Canfield Scientific Inc.; Medidata Solutions; Veeva Systems; Torii Pharmaceutical Co. Ltd.; Allucent (US) LLC; Myonex LLC

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 25, 2025Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments